HDAC9 and cancer: Pan-HDAC inhibitors (depsipeptide, hydroxamic acid analogs) induced acetylation of Hsp90 in human cancer cells, which prevented the binding of Hsp90 to client proteins (Yu et al., 2002; Nimmanapalli et al., 2003).